Non‑invasive microbiome and SCFA signatures could enable earlier PD diagnosis and patient stratification and point to gut–brain metabolic pathways amenable to biomarker‑guided trials or microbiome‑targeted interventions.

Provides a translational digital biomarker approach that sensitively distinguishes medication versus DBS effects, supporting personalized treatment profiling, improved monitoring, and more sensitive endpoints for clinical trials in Parkinson's disease.

Clinically and policy-relevant evidence that continuous subcutaneous LD/CD can lower care burden and overall costs—valuable for adoption and trial/pricing decisions—though it offers no novel mechanistic or biomarker insights for therapeutic discovery.

While not a molecular or drug-focused study, the paper is highly relevant to translational therapeutic development because aDBS provides a platform for validated physiological biomarkers, personalized symptom control, and integrated outcome measures that can accelerate development of…

Offers a noninvasive, objective biomarker for cognitive impairment in Parkinson's and Lewy body dementia that could aid patient stratification and serve as an electrophysiological endpoint for trials of cognitive-enhancing or disease-modifying therapies.

Offers a translational, high‑sensitivity wearable platform for real‑time levodopa monitoring to support personalized dosing and symptom management in Parkinson's patients, though it does not address disease mechanisms or new therapeutic targets.

This work pinpoints a specific hippocampal cell‑type circuit that modulates limbic dopamine/serotonin and alleviates PD‑related depression/anxiety, offering a plausible target for neuromodulation or circuit‑based therapies even though the chemogenetic approach itself is not yet directly…

Clinically relevant evidence that STN-DBS offers sustained motor benefit and appears cognitively safe over 3 years, informing treatment decisions and trial design despite offering little molecular/mechanistic insight for novel drug discovery.

By pinpointing cerebellar-thalamic circuit dysfunction in an alpha-synuclein model that manifests tremor, the work highlights a non-dopaminergic circuit-level target that could guide development of therapies or circuit-based interventions for PD symptoms refractory to dopamine replacement.

By linking fatigue to a specific sensorimotor processing deficit this study proposes a measurable biomarker and a mechanistic target (sensory attenuation circuitry) that could guide development of targeted neuromodulation, sensory retraining, or symptom-focused clinical trials for PD fatigue.

Structured, reliable VAS feedback can serve as a practical patient-reported digital biomarker to standardize and remote-optimize DBS programming and inform multimodal or closed-loop DBS strategies, improving therapeutic delivery though it does not address underlying disease biology.

This highlights early, pollution-associated alpha-synuclein accumulation as a potential environmental risk marker and cohort for biomarker development and prevention-focused studies relevant to Parkinson's, but offers limited mechanistic or direct therapeutic targets.

Provides clinically actionable evidence for a non-pharmacologic rehabilitation method that may reduce aspiration risk and improve quality of life in PwPD and guides design of larger confirmatory trials, though it has limited direct implication for molecular or disease-modifying therapeutic…

Offers a practical fallback imaging biomarker for detecting nigral changes and improving patient selection/stratification in trials when dedicated SMwI is unavailable, but provides limited direct insight into disease mechanisms or therapeutic targets.

While not mechanistic, the work documents early and progressive treatment of non-motor symptoms and a medication-related safety concern (falls/fractures) that could drive trials of safer symptomatic treatments, deprescribing interventions, or earlier non-pharmacologic management strategies.

Although not experimental, the paper identifies emerging mechanistic (brain–gut) and clinical (rehabilitation, early detection) priorities that can help prioritize translational research and inform therapeutic target selection for PD-related frailty.

Offers modest clinical relevance as a non-pharmacological symptomatic intervention that may inform rehabilitation practice and trial design, but has limited therapeutic discovery value for drug development due to small, uncontrolled sample and no mechanistic or biomarker data.

Clinically relevant for Parkinson's care and for trial/drug safety considerations (need for kidney monitoring and dose adjustments), but offers limited actionable mechanistic or targetable insight for Parkinson's therapeutic discovery.

The work identifies a potential spinal-level biomarker and mechanistic target for essential tremor interventions, but it offers limited direct actionable insight for Parkinson's therapeutic discovery.

This validates caregiver-reported dysphagia measures as reliable complementary endpoints for clinical monitoring and trials of swallowing interventions in PD, but offers limited mechanistic or therapeutic discovery insights.

While it provides little mechanistic or pharmacological insight for Parkinson's therapeutic discovery, the study supports targeting physical activity and cognitive engagement as adjunctive, non‑drug strategies and informs selection of cognitive endpoints and lifestyle covariates for PD clinical…

Low direct value for Parkinson's therapeutic discovery (no PD mechanisms or targets), but clinically important as a potentially reversible parkinsonism mimic, emphasizing thorough workup and repeat imaging in atypical or rapidly progressing cases.

The work is valuable for improving early cognitive screening and care pathways in PD—which can affect patient management and trial recruitment—but offers limited direct mechanistic or therapeutic discovery insights for drug development.

This paper has limited direct impact on Parkinson's therapeutic discovery (no mechanistic or drug-target insights) but is useful for clinical management, improving patient QOL and adherence—factors that can indirectly affect outcomes and trial conduct in PD research.

While not mechanistic, the identification of early emotional disturbances in prodromal DLB could inform clinical recognition of synuclein-related prodromal states and guide early symptomatic management or stratification in PD-spectrum research.